Le Lézard
Classified in: Health
Subjects: CPG, MAT

Premiers Focused on Public Health and Safety in the Legalization of Cannabis


SASKATOON, July 11, 2019 /CNW/ - The federal government legalized cannabis in October 2018. Premiers remain focused on protecting public health and safety, and combatting the illegal market for cannabis. Provinces and territories are responsible for significant aspects of this complex undertaking, and substantial costs have been incurred.

Premiers discussed the considerable progress provinces and territories have made in developing cannabis distribution, retail and oversight mechanisms under very tight federal timelines. However, they emphasized the need for the federal government to quickly address several outstanding concerns to support the health and safety of Canadians:

 

SOURCE Canada's Premiers


These press releases may also interest you

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...

at 05:45
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to  ResearchAndMarkets.com's offering....

at 05:45
The Gross Law Firm issues the following notice to shareholders of InMode Ltd. . Shareholders who purchased shares of INMD during the...

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:20
IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the...



News published on and distributed by: